JP5629947B2 - 植物抽出物およびpufaの組合せ - Google Patents
植物抽出物およびpufaの組合せ Download PDFInfo
- Publication number
- JP5629947B2 JP5629947B2 JP2011512974A JP2011512974A JP5629947B2 JP 5629947 B2 JP5629947 B2 JP 5629947B2 JP 2011512974 A JP2011512974 A JP 2011512974A JP 2011512974 A JP2011512974 A JP 2011512974A JP 5629947 B2 JP5629947 B2 JP 5629947B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- pufa
- oregano
- oregano extract
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title claims description 66
- 239000000419 plant extract Substances 0.000 title description 16
- 239000000284 extract Substances 0.000 claims description 83
- 240000007673 Origanum vulgare Species 0.000 claims description 78
- 235000013628 Lantana involucrata Nutrition 0.000 claims description 73
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 claims description 73
- 239000000203 mixture Substances 0.000 claims description 26
- 239000002775 capsule Substances 0.000 claims description 23
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 22
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 18
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 18
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 18
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 18
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 12
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 11
- 125000004494 ethyl ester group Chemical group 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 9
- KEQHJBNSCLWCAE-UHFFFAOYSA-N thymoquinone Chemical compound CC(C)C1=CC(=O)C(C)=CC1=O KEQHJBNSCLWCAE-UHFFFAOYSA-N 0.000 description 24
- 239000003921 oil Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 21
- 230000003647 oxidation Effects 0.000 description 17
- 238000007254 oxidation reaction Methods 0.000 description 17
- 239000003963 antioxidant agent Substances 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 8
- 235000007746 carvacrol Nutrition 0.000 description 8
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 8
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 8
- 235000020748 rosemary extract Nutrition 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940092258 rosemary extract Drugs 0.000 description 6
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 6
- 241000273930 Brevoortia tyrannus Species 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000007407 health benefit Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003244 pro-oxidative effect Effects 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000011203 Origanum Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 2
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- 241001529744 Origanum Species 0.000 description 2
- 240000000783 Origanum majorana Species 0.000 description 2
- 241001518075 Origanum minutiflorum Species 0.000 description 2
- 241000629988 Origanum vulgare subsp. virens Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 2
- -1 but not limited to Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229940117948 caryophyllene Drugs 0.000 description 2
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- YUFFSWGQGVEMMI-UHFFFAOYSA-N (7Z,10Z,13Z,16Z,19Z)-7,10,13,16,19-docosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCCC(O)=O YUFFSWGQGVEMMI-UHFFFAOYSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- IAZJMDOXZNDQGX-UHFFFAOYSA-N 2-methyl-5-propan-2-ylphenol;phenol Chemical compound OC1=CC=CC=C1.CC(C)C1=CC=C(C)C(O)=C1 IAZJMDOXZNDQGX-UHFFFAOYSA-N 0.000 description 1
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000273932 Brevoortia Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- 235000007129 Cuminum cyminum Nutrition 0.000 description 1
- TYLNXKAVUJJPMU-DNKOKRCQSA-N Docosahexaenoic acid ethyl ester Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OCC TYLNXKAVUJJPMU-DNKOKRCQSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000178435 Eliokarmos dubius Species 0.000 description 1
- 241001652112 Ethmidium Species 0.000 description 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
- 241000269820 Euthynnus affinis Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 229920001732 Lignosulfonate Polymers 0.000 description 1
- 241001604074 Lippia Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000010677 Origanum vulgare Nutrition 0.000 description 1
- 241000629989 Origanum vulgare subsp. hirtum Species 0.000 description 1
- 241001275912 Ornithodoros compactus Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000010688 Yerba dulce Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229930007927 cymene Natural products 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- XIVFQYWMMJWUCD-UHFFFAOYSA-N dihydrophaseic acid Natural products C1C(O)CC2(C)OCC1(C)C2(O)C=CC(C)=CC(O)=O XIVFQYWMMJWUCD-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940106134 krill oil Drugs 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- VORKGRIRMPBCCZ-UHFFFAOYSA-N methyl tricosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(=O)OC VORKGRIRMPBCCZ-UHFFFAOYSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000010661 oregano oil Substances 0.000 description 1
- 229940111617 oregano oil Drugs 0.000 description 1
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229940119224 salmon oil Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/06—Preservation of finished products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B5/00—Preserving by using additives, e.g. anti-oxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Medical Informatics (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
Description
本発明は、高い安定性を示す、オレガノ抽出物などの植物抽出物と多価不飽和脂肪酸または誘導体例えばエチルエステル(「PUFA EE」)との組合せに関する。さらに本発明は、このような組合せおよび/またはそれらの揮発性構成要素を含む食品組成物、栄養補助組成物および医薬組成物にも関する。
数多くの植物抽出物が、さまざまな医学的特性またはその他の健康上のメリットを有するものとして公知である。例えば、オレガノ抽出物は、国際公開第08/017484号パンフレットにおいて記述されているメリットなどのさまざまな精神的/情緒的メリットを有するものとして公知であり、この文献にはそれがバランスのとれた情緒および精神能力を維持する上で有用であることが示され、抗うつ剤として作用できることが記載されている。
本発明は、貯蔵安定性の増加を示すPUFAと少なくとも1つの植物抽出物の安定した組合せに関するものであり、ここでその組合せがオレガノ抽出物およびメンハーデン油の組合せではないことを条件とし、PUFAおよび植物抽出物の両方の濃度は少なくとも約8%である。
本発明で使用可能なPUFAは同様に、エステルなどのPUFA誘導体も含んでいる。その他の誘導体は、パルミチン酸エステルまたはその他の食用エステルを含む。1つの特に好ましいPUFA誘導体は、PUFAエチルエステル(PUFA EE)である。同様に本発明に含まれているのは、PUFAトリグリセリド(好ましくは最低25%のPUFA、より好ましくは30%のPUFA、特にEPAを富有するものである。
本発明で使用される植物抽出物は、任意の植物抽出物であってよいが、好ましいものとしては、オレガノ、タイム、リッピア、レモンバーム、カモミール、ホップ、バレリアン、オリーブ、マジョラム、セージ、月桂樹、ブラッククミン、カワカワ、ブラックペッパー、フェンネル、シナモン、朝鮮人参およびショウガおよびそれらの混合物が含まれる。
その重量に基づいて、
・ オレガノ抽出物が少なくとも30重量%のカルバクロールを含む、
・ オレガノ抽出物が少なくとも50重量%のカルバクロールを含む、そして
・ より好ましくは、オレガノ抽出物が少なくとも55重量%のカルバクロールを含む。
・ 好ましくは、オレガノ抽出物は少なくとも1重量%のチモキノンを含み、
・ より好ましくは、オレガノ抽出物は少なくとも2重量%のチモキノンを含み、
・ より好ましくは、オレガノ抽出物は少なくとも4重量%のチモキノンを含み、
・ 最も好ましくは、オレガノ抽出物は4〜30重量%の範囲内のチモキノンを含む。
・ 少なくとも50重量%のカルバクロールおよび0〜25重量%のチモキノンを含む;
・ 好ましくは、少なくとも50重量%のカルバクロールおよび少なくとも1重量%のチモキノンを含む;
・ より好ましくは、少なくとも55重量%のカルバクロールおよび少なくとも2重量%のチモキノンを含む;または
・ 少なくとも55重量%のカルバクロールおよび少なくとも4重量%のチモキノンを含むものである。
本発明のPUFAは、好ましくは、高濃度のn−3多価不飽和脂肪酸誘導体を含む。好ましくはこれらはエステルの形をとり、好ましくはエイコサペンタエン酸エチルエステル(EPA EE)およびドコサヘキサエン酸エチルエステル(DHA EE)の形をとる。好ましい実施形態においては、PUFAは、調製物中に少なくとも約60重量%の濃度、より好ましくは少なくとも約70重量%の濃度、そして最も好ましくは少なくとも約75重量%の量で存在する。PUFA調製物は、必要に応じてさらなる担体油を含んでいてよい。
本発明の好ましい実施形態において、オレガノ抽出物およびPUFA EEは8:92〜92:8の比率(重量%)で存在する。より好ましい実施形態においては、オレガノの比率は、混合物の少なくとも8%、好ましくは少なくとも約25%であり、少なくとも約50%であってよい。これらの比率は、本発明の2つの態様を提供する。すなわち、酸化促進効果が全く観察されることなく安定性が得られること、そして第2に、PUFA EEとオレガノ抽出物の両方が、この混合物を摂取する人に対して共に生物活性効果を及ぼすのに充分な高い濃度で存在することである。
[実施例1]
[材料の調製]
[オレガノ抽出物]
オリガナム・ブルガレ(Origanum vulgare)またはO.ミヌチフロラム(O.minutiflorum)の乾燥した葉および花を、天然二酸化炭素を用いた超臨界流体抽出により抽出した。抽出物は、Flavex Naturextrakte GmbHから得た。
[酸化安定性]
酸化に対する脂質溶液試料の相対的安定性を、Oxipres装置を用いた加速酸化試験において測定した。初期条件を70℃および5〜6バールにセットした。ML OXIPRES(商標)(Mikrolab Aarhus A/S、Denmark)装置は、加圧下の酸素を用いた酸化に基づく改良ボンベ方法である。Gearhart 1957 J.Amer.Oil Chem.Soc 34:427およびStuckey et al J.Amer.Oil Chem.Soc.35:581およびBlankenship et al 1973 J.Amer.Oil Chem. Soc.50:377−318を参照されたい。試験は高圧で行なわれた場合に加速される。酸素消費量は、実験中のボンベ内の圧力降下により決定される。
図1は、純粋なROPUFA「75」n−3 EE油(オレガノ抽出物0%)の酸化が、異なるオレガノ抽出物濃度(8%および25%)で混合溶液試料を用いた場合よりも急速であることを示している。約65時間後、オレガノ抽出物の酸化阻害能力は、オレガノ濃度の上昇に伴い有意に増大する。純粋オレガノ抽出物(100%)についての曲線は、ブランク試料に比べて有意に減少せず、こうして純粋オレガノ抽出物が安定していること実証している。
[PUFA分析]
EPA、DHAおよびDPAの同定を、真正基準標準(authentic reference standard)と保持時間を比較することによって行なった。トリコサノン酸メチルエステルを用いた内部標準較正を適用することにより定量化を実施した。
[ソフトゲルキャップ]
サイズ16(体積=0.985)の細長いソフトゼラチンカプセルを、一般に公知の技術にしたがって調製し、これは以下の組成を含む:
Claims (5)
- オレガノ抽出物および多価不飽和脂肪酸(PUFA)またはPUFAの誘導体を含む安定した組成物であって、前記オレガノ抽出物が少なくとも15重量%の量で存在し、前記PUFAまたはPUFAの誘導体は、少なくとも30%のエイコサペンタエン酸もしくはそのエチルエステル、ドコサヘキサエン酸もしくはそのエチルエステルまたはそれらの混合物を含む、組成物。
- 前記PUFAの誘導体がPUFAエチルエステルである、請求項1に記載の組成物。
- カプセルである、請求項1に記載の組成物。
- 少なくとも約3.5%のオレガノ抽出物を含む、請求項3に記載のカプセル。
- 請求項1に記載の組成物を含む食品。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08010506.7 | 2008-06-10 | ||
EP08010506 | 2008-06-10 | ||
EP08010653.7 | 2008-06-12 | ||
EP08010653 | 2008-06-12 | ||
PCT/EP2009/057189 WO2009150179A2 (en) | 2008-06-10 | 2009-06-10 | Plant extract and pufa combinations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014152305A Division JP2014237680A (ja) | 2008-06-10 | 2014-07-25 | 植物抽出物およびpufaの組合せ |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011523856A JP2011523856A (ja) | 2011-08-25 |
JP5629947B2 true JP5629947B2 (ja) | 2014-11-26 |
Family
ID=40983512
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011512974A Expired - Fee Related JP5629947B2 (ja) | 2008-06-10 | 2009-06-10 | 植物抽出物およびpufaの組合せ |
JP2014152305A Pending JP2014237680A (ja) | 2008-06-10 | 2014-07-25 | 植物抽出物およびpufaの組合せ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014152305A Pending JP2014237680A (ja) | 2008-06-10 | 2014-07-25 | 植物抽出物およびpufaの組合せ |
Country Status (8)
Country | Link |
---|---|
US (1) | US20110189315A1 (ja) |
EP (1) | EP2285242B1 (ja) |
JP (2) | JP5629947B2 (ja) |
KR (1) | KR20110044968A (ja) |
CN (1) | CN102118981A (ja) |
ES (1) | ES2420979T3 (ja) |
PL (1) | PL2285242T3 (ja) |
WO (1) | WO2009150179A2 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010138902A1 (en) | 2009-05-29 | 2010-12-02 | New Chapter Inc. | Compositions and methods for modulating lipid composition |
WO2014006532A1 (en) * | 2012-07-02 | 2014-01-09 | Dsm Ip Assets B.V. | Capsules containing thymoquinone |
CA3069902A1 (en) * | 2017-07-15 | 2019-01-24 | Trinutra Ltd. | Compositions comprising thymoquinone and omega-3 fatty acids |
BR112021007396A2 (pt) * | 2018-10-22 | 2021-08-03 | Dsm Ip Assets B.V. | composição que exibe estabilidade oxidativa melhorada |
CN109673850A (zh) * | 2019-01-31 | 2019-04-26 | 石家庄石牧动物药业有限公司 | 一种多功能粉末油脂及其制备方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU552068B2 (en) * | 1981-09-21 | 1986-05-22 | Asama Chemical Co. Ltd. | Preservation of edible oils |
JPS5852215A (ja) * | 1981-09-21 | 1983-03-28 | Asama Kasei Kk | 不飽和油脂含有軟カプセル製剤 |
US5017397A (en) * | 1990-04-25 | 1991-05-21 | Uy Nguyen | Process for extracting antioxidants from Labiatae herbs |
US5147854A (en) * | 1990-05-22 | 1992-09-15 | Hoffmann-La Roche Inc. | Tgf-b compositions and method |
GB9321479D0 (en) * | 1993-10-18 | 1993-12-08 | Scotia Holdings Plc | Stabilisation of polyunsaturates |
JPH07236418A (ja) * | 1994-02-25 | 1995-09-12 | Kanegafuchi Chem Ind Co Ltd | ドコサヘキサエン酸、エイコサペンタエン酸用抗酸化矯臭剤 |
US20030232100A1 (en) * | 1998-04-08 | 2003-12-18 | Theoharides Theoharis C. | Compositions for treatment of diseases arising from secretion of mast cell biochemicals |
US7906153B2 (en) * | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
US5955102A (en) * | 1998-09-04 | 1999-09-21 | Amway Corporation | Softgel capsule containing DHA and antioxidants |
ZA994696B (en) * | 1998-09-09 | 2000-01-31 | Pharmachoice Healthcare Pty Lt | Nutritional healthcare formulation. |
PT1156814E (pt) * | 1999-03-03 | 2004-01-30 | Eurovita A S | Compostos farmaceuticos suplementos dieteticos e composicoes cosmeticas compreendendo um acido gordo e gengibre |
US20020119237A1 (en) * | 2000-12-22 | 2002-08-29 | Hevey Maurice O. | Medium and method for delivery of edible materials subject to degradation by oxidation and hydrolysis |
KR20020071326A (ko) * | 2001-03-06 | 2002-09-12 | 팍스바이오젠 주식회사 | 발기부전 개선용 조성물 및 이를 함유하는 식품 |
NL1019368C2 (nl) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
EP1673423B1 (en) * | 2003-10-21 | 2008-12-10 | DSM IP Assets B.V. | Stabilisation of polyunsaturated fatty acid (pufa) ester concentrates |
FR2887748B1 (fr) * | 2005-06-29 | 2009-09-04 | Physcience Soc Par Actions Sim | Complement alimentaire et son utilisation pour la prevention ou la lutte contre les effets des affections articulaires. |
ITRM20050437A1 (it) * | 2005-08-09 | 2007-02-10 | Sipa Societa Industrializzazio | Dispositivo e processo di essiccazione di materiale plastico per una macchina di produzione di contenitori in plastica. |
JP2009526644A (ja) * | 2006-02-15 | 2009-07-23 | ボタノキャップ リミテッド | マイクロカプセル化した精油の応用 |
US20090304784A1 (en) * | 2006-07-28 | 2009-12-10 | V. Mane Fils | Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component |
ITBA20060049A1 (it) * | 2006-08-02 | 2008-02-03 | Pierre S R L | Integratore alimentare a base di licopene biologico e procedimento per l'ottenimento del licopene biologico. |
EP2049132B1 (en) * | 2006-08-09 | 2012-12-05 | DSM IP Assets B.V. | Novel agents for the treatment of disorders connected to impaired neurotransmission |
DE102006041905A1 (de) * | 2006-09-07 | 2008-03-27 | Cognis Ip Management Gmbh | Zubereitungen zur oralen Aufnahme (I) |
-
2009
- 2009-06-10 ES ES09761742T patent/ES2420979T3/es active Active
- 2009-06-10 US US12/997,045 patent/US20110189315A1/en not_active Abandoned
- 2009-06-10 KR KR1020117000550A patent/KR20110044968A/ko not_active Application Discontinuation
- 2009-06-10 EP EP09761742.7A patent/EP2285242B1/en active Active
- 2009-06-10 WO PCT/EP2009/057189 patent/WO2009150179A2/en active Application Filing
- 2009-06-10 PL PL09761742T patent/PL2285242T3/pl unknown
- 2009-06-10 CN CN2009801311081A patent/CN102118981A/zh active Pending
- 2009-06-10 JP JP2011512974A patent/JP5629947B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-25 JP JP2014152305A patent/JP2014237680A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20110189315A1 (en) | 2011-08-04 |
KR20110044968A (ko) | 2011-05-03 |
EP2285242A2 (en) | 2011-02-23 |
JP2011523856A (ja) | 2011-08-25 |
ES2420979T3 (es) | 2013-08-28 |
JP2014237680A (ja) | 2014-12-18 |
CN102118981A (zh) | 2011-07-06 |
EP2285242B1 (en) | 2013-05-01 |
WO2009150179A2 (en) | 2009-12-17 |
WO2009150179A3 (en) | 2010-02-04 |
PL2285242T3 (pl) | 2013-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20140062514A (ko) | 들깨로부터 유래한 필수 지방산이 풍부한 식물 유래 씨드 추출물: 물질의 조성물, 제조 방법 및 용도 | |
CA2694054A1 (en) | Omega-3 fatty acid fortified composition | |
JP2014237680A (ja) | 植物抽出物およびpufaの組合せ | |
WO2006056293A1 (en) | Oral composition for enhancing skin properties | |
TWI720184B (zh) | 分離型液體調味料、及分離型液體調味料之製造方法 | |
Bhanger et al. | Cold pressed apricot (Prunus armeniaca L.) kernel oil | |
JP6083942B2 (ja) | 長命草及び魚介油を含む組成物 | |
JP6444583B2 (ja) | 経口組成物 | |
JP2017500429A (ja) | 海産油、動物油または植物油の酸化安定化のための抗酸化組成物 | |
Tohma et al. | Efficacy of rosemary (Rosmarinus officinalis L.) powder and extracts in the protection of refined and stripped hazelnut oil | |
JP6450317B2 (ja) | Dha及びepaを含む軟カプセル | |
EP3000867B1 (en) | Fat composition | |
JP7016810B2 (ja) | 液体油および粉末原料の混合可食性組成物、並びにその製造方法 | |
CA3136124A1 (en) | Novel hemp and pea formulation and its use | |
Ponphaiboon et al. | Development and Evaluation of a Dry Emulsion of Ostrich Oil as a Dietary Supplement | |
JP4997514B2 (ja) | 血圧上昇抑制剤 | |
JP2018050566A (ja) | アンペロプシンと魚油を含有する食品組成物 | |
Shahidi et al. | Dietary Lipid Supplements | |
Ouhtit et al. | Morphometry, Oil Yield and Fatty Acid Profile of Cannabis Achenes from the Chefchaouen Region | |
JP6891031B2 (ja) | 乳化液状調味料 | |
JP2022503799A (ja) | 向上した酸化安定性を示す組成物 | |
JP2020150822A (ja) | 油脂、油脂の製造方法、および油脂用酸化抑制剤 | |
JP2018050567A (ja) | ヒドロキシチロソールと魚油を含有する食品組成物 | |
RU2211043C2 (ru) | Композиция для приготовления лекарственных форм и обогащения продуктов питания, способствующая коррекции нарушений липидного обмена, профилактики и лечения атеросклероза | |
Templeman | Gel Encapsulation Technology Development for the Purpose of Safeguarding an Active Ingredient (Holy Basil; Ocimum sanctum) from Ruminal Degradation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120510 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130614 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131009 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140725 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140805 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140909 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140918 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5629947 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |